Enter your email address
Submit
Write your message
Bankole Emmanuel Ofeniforo *1 
, Olalekan Bukunmi Ogunro2 , Johnson O. Oladele3 , Samuel Eleojo Agada4 , Oluwaseun Dorcas Ayo-Dada5 , Olukemi Omolade Ogunyebi6 , Morenike Grace Ajayi7
, Olalekan Bukunmi Ogunro2 , Johnson O. Oladele3 , Samuel Eleojo Agada4 , Oluwaseun Dorcas Ayo-Dada5 , Olukemi Omolade Ogunyebi6 , Morenike Grace Ajayi7
1- Biochemistry Unit, Department of Chemical Sciences, Bamidele Olumilua, University of Education, Science and Technology, Ikere, Nigeria. , ofeniforo.bankole@bouesti.edu.ng
2- Biochemistry Unit, Department of Biological Sciences, KolaDaisi University, Ibadan, Nigeria.
3- Royal Scientific Research Institute, Osun State, Nigeria.
4- Microbiome and Molecular Host-Pathogen Interactions Unit, Department of Poultry Science, Texas A&M University, Texas, USA.
5- Public Health Unit, Department of Health Sciences, Bamidele Olumilua University of Education, Science and Technology, Ikere, Nigeria.
6- Biochemistry Unit, Department of Chemical Sciences, Bamidele Olumilua University of Education, Science and Technology, Ikere, Nigeria
7- Chemistry (Analytical Chemistry) Unit, Department of Chemical Sciences, Bamidele Olumilua University of Education, Science and Technology, Ikere, Nigeria.
2- Biochemistry Unit, Department of Biological Sciences, KolaDaisi University, Ibadan, Nigeria.
3- Royal Scientific Research Institute, Osun State, Nigeria.
4- Microbiome and Molecular Host-Pathogen Interactions Unit, Department of Poultry Science, Texas A&M University, Texas, USA.
5- Public Health Unit, Department of Health Sciences, Bamidele Olumilua University of Education, Science and Technology, Ikere, Nigeria.
6- Biochemistry Unit, Department of Chemical Sciences, Bamidele Olumilua University of Education, Science and Technology, Ikere, Nigeria
7- Chemistry (Analytical Chemistry) Unit, Department of Chemical Sciences, Bamidele Olumilua University of Education, Science and Technology, Ikere, Nigeria.
Abstract: (15 Views)
Background and Aims: Medicinal plants, including Spilanthes filicaulis, have been cornerstone treatments in the traditional primary healthcare system, mainly in tropical African countries. This versatile plant is extensively used to treat and manage various health conditions. In this regard, the present study aimed to amplify scientific evidence about the safety level of Ethylacetate Subfraction of Spilanthes filicaulis (ESSF).
Materials and Methods: A Toxicological study was conducted on 72 male Rattus norvegicus, divided into six groups (n=12) with weight ranges of 140-156 g. Group 1 served as the control group, receiving 10 ml/kg body weight distilled water daily, while Groups 2-6 received graded doses ranging from 62.50 to 750 mg/kg body weight of the extracts, respectively, once daily for 28 days. On days 14 and 28 after the treatment, rats underwent fasting for 12 h overnight and euthanized. Lipid profile and cellular enzymes tests (alanine aminotransferase [ALT], aspartate aminotransferase [AST], Gamma-Glutamyltransferase [GGT], Lactate Dehydrogenase [LDH], and Acetylcholine esterase [AchE]) were evaluated on prepared tissues (serum, brain, liver, and kidney). Histoarchitecture of vital organs was also done.
Results: The ESSF at most of the doses investigated on the rats did not significantly alter serum concentrations of lipid on days 14 and 28, compared to the control group (p>0.05). Additionally, the ESSF of all doses did not significantly alter the activities of ALT, AST, GGT, LDH, and AChE in most of the studied tissues on days 14 and 28, compared to the control group (p>0.05).
Conclusion: No abnormalities were found in the organs of treated animals during the histological analysis. Consequently, R. norvegicus treated with ESSF did not experience harmful effects.
Materials and Methods: A Toxicological study was conducted on 72 male Rattus norvegicus, divided into six groups (n=12) with weight ranges of 140-156 g. Group 1 served as the control group, receiving 10 ml/kg body weight distilled water daily, while Groups 2-6 received graded doses ranging from 62.50 to 750 mg/kg body weight of the extracts, respectively, once daily for 28 days. On days 14 and 28 after the treatment, rats underwent fasting for 12 h overnight and euthanized. Lipid profile and cellular enzymes tests (alanine aminotransferase [ALT], aspartate aminotransferase [AST], Gamma-Glutamyltransferase [GGT], Lactate Dehydrogenase [LDH], and Acetylcholine esterase [AchE]) were evaluated on prepared tissues (serum, brain, liver, and kidney). Histoarchitecture of vital organs was also done.
Results: The ESSF at most of the doses investigated on the rats did not significantly alter serum concentrations of lipid on days 14 and 28, compared to the control group (p>0.05). Additionally, the ESSF of all doses did not significantly alter the activities of ALT, AST, GGT, LDH, and AChE in most of the studied tissues on days 14 and 28, compared to the control group (p>0.05).
Conclusion: No abnormalities were found in the organs of treated animals during the histological analysis. Consequently, R. norvegicus treated with ESSF did not experience harmful effects.
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
The Iranian Journal of Toxicology
Arak University of Medical Sciences in collaboration with the Iranian Society of Toxicology
Website: http://ijt.arakmu.ac.ir
Email: tox.journal@gmail.com
